We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Dynavax Technologies Corp | NASDAQ:DVAX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.02 | 0.17% | 11.74 | 11.46 | 11.74 | 12.06 | 11.71 | 11.87 | 1,817,395 | 22:24:22 |
The details of the poster presentations and discussion sessions are as follows:
Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Poster Discussion Session: Head and Neck CancersFinal Publication Number: 1050PDDiscussion Session Date/Time: Saturday, October 20, 2018, 3:00 PM - 4:15 PM CEST Discussion Session Location: Hall B3 - Room 23, ICM München, Munich GermanyPoster Session Date/Time: Saturday, October 20, 9:00 AM CEST to Monday, October 22, 5:00 PM CESTPoster Session Location: Hall B4 – ICM München, Munich Germany
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy
Poster Discussion Session: Melanoma and Other Skin TumoursFinal Publication Number: LBA45Discussion Session Date/Time: Saturday, October 20, 2018, 2:45 PM - 4:05 PM CESTDiscussion Session Location: ICM - Room 14b, ICM München, Munich GermanyPoster Session Date/Time: Saturday, October 20, 2:45 PM CEST to Monday, October 22, 5:00 PM CESTPoster Session Location: Hall B4 – ICM München, Munich Germany
Phase Ib/II study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who had progressive disease on or after prior anti-PD-1 therapy
Poster Session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathologyFinal Publication Number: 1265PPoster Session Date/Time: Sunday, October 21, 12:45 PM - 1:45 PM CESTPoster Session Location: Hall A3 – Poster Area Networking Hub, ICM München, Munich Germany
About SD-101SD-101, the Company's lead clinical candidate, is a proprietary, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide. Dynavax is evaluating this intratumoral TLR9 agonist in several clinical studies to assess its safety and activity, including a Phase 2 study in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy, in patients with advanced melanoma and in patients with head and neck squamous cell cancer, in a clinical collaboration with Merck. Dynavax maintains all commercial rights to SD-101.
About DynavaxDynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in January 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Contact: Ryan SpencerVice President, Corporate Strategy and Communications510.665.4618 | Media Contact:Rachel St. MartinW2O 646.894.5757 rstmartin@w2ogroup.com |
1 Year Dynavax Technologies Chart |
1 Month Dynavax Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions